Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

318
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
318
Tumor Immunotherapy01:27

Tumor Immunotherapy

501
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
501
Hybridoma Technology01:31

Hybridoma Technology

14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Blood advances·2026
Same author

Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.

Cancer research communications·2026
Same author

Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma.

Leukemia & lymphoma·2026
Same author

Mutational Profiling Links Biologically Relevant Variants to Multi-Systemic Rosai-Dorfman Disease.

Blood advances·2026
Same author

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Blood·2026

Related Experiment Video

Updated: Jun 19, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

IgG replacement in multiple myeloma.

Alex Wonnaparhown1, Talal Hilal2, Jacqueline Squire3

  • 1Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Phoenix, AZ, USA. Wonnaparhown.Alex@mayo.edu.

Blood Cancer Journal
|July 25, 2024
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor T cell therapy and bispecific antibodies improve multiple myeloma outcomes but cause hypogammaglobulinemia. Immunoglobulin G replacement therapy shows promise for managing infections in these patients.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Related Experiment Videos

Last Updated: Jun 19, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • T cell engagers (TCE), including chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies (BiAbs), have revolutionized multiple myeloma (MM) treatment.
  • These advanced therapies are associated with secondary immunodeficiency and hypogammaglobulinemia (HG), leading to recurrent infections.
  • As MM patients live longer, managing therapy-associated infections and morbidity is crucial.

Purpose of the Study:

  • To review the infection risks and hypogammaglobulinemia associated with TCE in multiple myeloma.
  • To discuss the current and potential strategies for managing hypogammaglobulinemia using immunoglobulin G replacement therapy (IgG-RT) in MM patients post-TCE.
  • To highlight the need for standardized protocols for IgG-RT in this patient population.

Main Methods:

  • This review synthesizes existing literature on TCE in multiple myeloma, focusing on secondary immunodeficiency and hypogammaglobulinemia.
  • It examines the application of immunoglobulin G replacement therapy (IgG-RT) principles from primary immunodeficiency to MM.
  • The review discusses clinical outcomes, challenges, and future directions for IgG-RT management in MM patients treated with TCE.

Main Results:

  • TCE treatments significantly improve clinical outcomes in multiple myeloma but increase the risk of HG and subsequent infections.
  • Immunoglobulin G replacement therapy (IgG-RT), a standard in primary immunodeficiency, is showing promising results in managing HG and infections in MM patients post-TCE.
  • However, specific guidelines for IgG-RT initiation, dosing, and monitoring in MM patients treated with TCE are currently lacking.

Conclusions:

  • Effective management of secondary immunodeficiency and hypogammaglobulinemia is essential for improving long-term outcomes in multiple myeloma patients treated with TCE.
  • Further research and standardization of immunoglobulin G replacement therapy (IgG-RT) protocols are needed for optimal patient care.
  • Future progress in multiple myeloma treatment will involve better recognition of immunodeficiency, risk stratification, and integrated management strategies including IgG-RT.